Navigation Links
PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
Date:2/18/2009

cts or overrun cost estimates and the effect on our financial results by failure to receive approval for change orders and by delays in documenting change orders, our ability to implement our business strategy, international economic, political and other risks that could negatively affect our results of operations or financial position, changes in outsourcing trends and regulatory requirements affecting the branded pharmaceutical, biotechnology, generic drug and medical device industries, the reduction of expenditures by branded pharmaceutical, biotechnology, generic drug or medical device companies, actions or inspections by regulatory authorities and the impact on our clients' decisions to not award future contracts to us or to cancel existing contracts, the impact of healthcare reform, the fact that one or a limited number of clients may account for a large percentage of our revenues, the incurrence of significant taxes to repatriate funds, the fluctuation of our operating results from period to period, our assessment of our goodwill valuation, the impact of foreign currency fluctuations, tax law changes in Canada or in other foreign jurisdictions, investigations by governmental authorities regarding our inter-company transfer pricing policies or changes to their laws in a manner that could increase our effective tax rate or otherwise harm our business, our lack of the resources needed to compete effectively with larger competitors, our ability to continue to develop new assay methods for our analytical applications, or if our current assay methods are incorrect, our ability to compete with other entities offering bioanalytical laboratory services, our potential liability when conducting clinical trials, our handling and disposal of medical wastes, failure to comply with applicable governmental regulations, the loss of services of our key personnel and our ability to attract qualified staff, the continued effectiveness and availability of our information technolo
'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PharmaNet Development Group Agrees to be Acquired by JLL Partners
2. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new ... The tour and course will be given every Wednesday at 6pm to local interested ... members are welcome to attend with their veterinarian as well. Participants will be able ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
(Date:7/28/2015)... and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 /PRNewswire/ ... announced its financial results for the second quarter ... grew nearly 300% as compared to the second ... launched," said Roger Jeffs, Ph.D., United Therapeutics, President ... sales was due to an increase in the ...
(Date:7/27/2015)... and FRANKLIN, Tenn. ... a privately-owned  premier provider of health care services ... in the U.S., today announced that its parent ... signed a definitive agreement with Medical Properties Trust, ... acquisition of Capella for $900 million in cash.  The transaction ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5
... May 1 Orchid Cellmark Inc.,(Nasdaq: ORCH ), ... release its first quarter 2008 financial results on,Thursday, May ... hosting a,conference call and webcast to discuss the results ... discuss financial results for the first quarter,2008 as well ...
... April 30 BioMed Realty Trust, Inc.,(NYSE: BMR ... lease for more,than 140,000 square feet at the Pacific ... Inc.,(Nasdaq: DSTI ) will join BioMed,s rapidly expanding ... East Bay of San Francisco,s thriving,technology corridor., DayStar ...
... DIEGO, April 30 Gen-Probe Incorporated,(Nasdaq: GPRO ) ... Bank 33rd Annual Health Care Conference on May 6 ... to be webcast live,and may be accessed through a ... http://www.gen-probe.com . The webcast will be available for 30,days ...
Cached Biology Technology:Orchid Cellmark to Announce First Quarter 2008 Financial Results on May 8, 2008 2BioMed Realty Trust Announces 140,000 Square Foot Lease With DayStar Technologies at Pacific Research Center 2BioMed Realty Trust Announces 140,000 Square Foot Lease With DayStar Technologies at Pacific Research Center 3Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference 2
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... bond is reflected by the similarity of their scents, finds ... but with smells instead of sounds," said Christine Drea, a ... researchers sampled and analyzed scent secretions produced by lemurs known ... Durham, NC. The researchers also monitored the animals, scent-marking and ...
... known for its role in digestion. But this collection of organs ... it is one of the first parts of the body that ... how the virus infects cells and accumulates in this area is ... worldwide living with HIV. Researchers at the California Institute of Technology ...
... allow yourself to be exposed to smoke because second-hand smoke ... says a scientist at the University of California, Riverside who, ... effects of third-hand smoke. While first-hand smoke refers to ... the exhaled smoke and other substances emanating from the burning ...
Cached Biology News:Lemur lovers sync their scents 2Lemur lovers sync their scents 3A detailed look at HIV in action 2A detailed look at HIV in action 3Third-hand smoke shown to cause health problems 2Third-hand smoke shown to cause health problems 3Third-hand smoke shown to cause health problems 4
... mouth PYREX Fernbach-style culture flask is designed for ... volume ratio. It can also be used in ... edges to achieve maximal oxygen transfer to culture ... and accepts cotton plugs or No. 13 rubber ...
... 30 isolations. The kit provides a ... apoptotic cells from normal c lture using ... is a Ca2+-dependent phospholipid binding protein with ... Cell Isolation Kit provides a simple and ...
... 5mm diameter, 7 inch long PYREX NMR tubes ... with ground joints, valves, and vacuum racks. They ... from 300 to 500MHz. They have an O.D. ... 4.20 + 0.013-0.000mm. These NMR tubes can be ...
Standard Fluka For microscopy (Hist.) redox indicator...
Biology Products: